UZ Leuven
Leuven, Vlaams-Brabant, 3000, Belgium
NCT Number: NCT03755388
The goal of this study is to evaluate the efficacy, safety and performance of the Episealer® device in a sample size of 30 patients and on the long term (10 years follow-up).
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Interventional
Not applicable
Leuven, Vlaams-Brabant, 3000, Belgium
Lesions in the cartilage are common disorders. In the knee, cartilage lesions are found in over 50 % of all arthroscopies, where 25 % of these are of focal character and the majority are found in the medial femoral condyle. The quality of life of patients with focal cartilage defects is significantly affected and it has been shown that the quality of life is affected to the same extend as in patients scheduled for knee replacement. Arthroscopy lavage and debridement micro fracturing, mosaic plasticity as well as osteochondral autograft transplantation (OATS) are methods used for treatment of the lesions. Some have shown to help the patients but there is an ongoing treatment gap especially for patients with knee lesions and early osteoarthritis.
Episurf Medical has developed a Focal Knee Resurfacing (FKR) implant, the Episealer® implant. The implant is used for treatment of focal cartilage lesions of the lateral or medial femoral condyle in order to alleviate pain and improve range of motion. The implant and surgical instruments are customized to each patient's joint anatomy, position, and size of injury, based on patient-specific images (MRI). The Episealer® device is CE marked.
The Episealer® implant consists of a peg and a hat. The implant exists in five different diameters (12,14,17, 20 and 25mm), depending on the lesion size. The shape of the hat is circular or oval.
The Episealer® implant is made of biocompatible cobalt/chromium/molybdenum alloy. To enhance the osseointegration, the implant is coated with biocompatible hydroxyapatite onto an interlaying biocompatible pure titanium coating.
A previous study (S57685) showed that Episealer is a viable option for focal cartilage lesions of the distal femur not responding, or not eligible for, biological treatment options (eg. microfracturing). This device is a good solution when there are no alternative treatments, except prosthesis surgery, available.
The goal is to evaluate the efficacy, safety and performance of the Episealer® device in a larger sample size and on the long term.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Placing Episealer device
Time frame: 10 years
Presence of the implant in the patient up to 10 years post treatment with loss/revision of the primary implant as endpoint
Time frame: 10 years
Efficacy will be evaluated with the comparison of the pre- and post- operative radiographs
Time frame: 10 years
Performance will be evaluated with the comparison of the pre- and post- operative KOOS-scores. Scoring: each item is scored between 0 and 4 and the raw score of each section is the sum or item scores. The score is then converted into a 0-100 scale. A higher score indicates fewer problems
Time frame: 10 years
Performance will be evaluated with the comparison of the pre- and post- operative VAS-scores. Score between 0 and 10. Higher score indicates more pain.
Time frame: 10 years
Safety will be evaluated by monitoring AEs, unanticipated device effects and subsequent interventions through 10 years post treatment
Universitaire Ziekenhuizen KU Leuven
Other
Long-term Prospective Interventional Clinical Trial of an MRI Based Patient Specific Focal Knee Resurfacing Implant
Acronym: Episealer2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04118023
Arthropathy of Knee, Cartilage Damage
Houston, Texas, United States
View Trial DetailsNCT03873545
Cartilage Damage, Cartilage Injury
Chicago, Illinois, United States
View Trial DetailsNCT06644092
Allograft, Arthritis
Istanbul, Atasehir, Turkey (Türkiye)
View Trial DetailsNCT06915363
Arthritis, Cartilage Damage
Fort Wayne, Indiana, United States
View Trial Details